40
A Primer on Clinical Trials for the Research Administrator David Lynch – Executive Director of Office of Sponsored Research, Northwestern University Mike Ritz – Research Compliance Officer, University of Rochester Tom Wilson – Senior Research Administrator and Asst. Vice President Rush University Medical Center

A Primer on Clinical Trials for the Research Administrator David Lynch –

Embed Size (px)

DESCRIPTION

A Primer on Clinical Trials for the Research Administrator David Lynch – Executive Director of Office of Sponsored Research, Northwestern University Mike Ritz – Research Compliance Officer, University of Rochester Tom Wilson – Senior Research Administrator and Asst. Vice President - PowerPoint PPT Presentation

Citation preview

Page 1: A Primer on Clinical Trials for the  Research Administrator David Lynch –

A Primer on Clinical Trials for the Research Administrator

David Lynch – Executive Director of Office of Sponsored Research, Northwestern University

Mike Ritz – Research Compliance Officer, University of Rochester

Tom Wilson – Senior Research Administrator and Asst. Vice President Rush University Medical Center

Page 2: A Primer on Clinical Trials for the  Research Administrator David Lynch –

Contents of Chapter One “An Introduction to Clinical Research”

• Definitions of Clinical Trial Terms• Phases of a Clinical Trial• Clinical Research Requirements

and Regulations• Clinical Trial Requirements and Regulations

Page 3: A Primer on Clinical Trials for the  Research Administrator David Lynch –

Clinical Research Requirements and Regulations –Protection of Human Subjects

– FDA regulations– DHHS regulations– The Common Rule

While there are some differences, the basicrequirements of an institutional assurance approvedby DHHS, review of research by an IRB, theinformed consent of subjects, and education andtraining are similar.

Page 4: A Primer on Clinical Trials for the  Research Administrator David Lynch –

Clinical Research Requirements and Regulations -Protection of Human Subjects

– Human Subjects Protection Training

Individuals who will be involved in the design or conduct of NIH-funded human subjects researchmust fulfill the NIH education requirement.

Page 5: A Primer on Clinical Trials for the  Research Administrator David Lynch –

Clinical Trial Requirements and Regulations -Investigational New Drug (IND) Application

Current federal law requires that a drug be subjectof an approved marketing application before it istransported or distributed across state lines. TheIND application is the means through which thesponsor obtains the exemption.

Page 6: A Primer on Clinical Trials for the  Research Administrator David Lynch –

Clinical Trial Requirements and Regulations -Investigational Device Exemption (IDE)

– Required prior to initiation of an investigational device study

– Approval required from the Medicare Administrative Contractor and local carrier before Medicare can be billed for participants enrolled in a study.

Page 7: A Primer on Clinical Trials for the  Research Administrator David Lynch –

Clinical Trial Requirements and Regulations -Medicare Coverage for Clinical Trials

– As stated in the National Coverage Determination, Medicare covers the routine costs of qualifying (as defined) clinical trials, as well as reasonable and necessary items and services used to diagnose and treat complications arising from participation in clinical trials.

Page 8: A Primer on Clinical Trials for the  Research Administrator David Lynch –

Contents of Chapter Two“Preparing a Clinical Trial Budget”

• Key Principles for Budgeting• Budgeting for Clinical Trials, other than Device

Studies• Budgeting for Device Studies• Negotiation Tips• Appendix with Templates

Page 9: A Primer on Clinical Trials for the  Research Administrator David Lynch –

Clinical Trials Other Than Device Studies• Prospective Reimbursement Analysis (PRA)

– Identify all procedures, items and tests within a clinical trial and to whom they are billable

– Two Steps• Is it a qualifying trial (as defined)?• If so, what costs can or cannot be charged to

insurance?

Page 10: A Primer on Clinical Trials for the  Research Administrator David Lynch –

Clinical Trials Other Than Device Studies

Text provides an example of a template for documenting the PRA.

Page 11: A Primer on Clinical Trials for the  Research Administrator David Lynch –

Device Studies– Medicare reimbursement depends on the category the

FDA assigns to the device (Category A or Category B).

– Costs associated with Category A devices are generally not covered by Medicare.

– Device and routine costs associated with Category B devices might be reimbursable if approved by the Medicare Administrative Contractor.

Page 12: A Primer on Clinical Trials for the  Research Administrator David Lynch –

All Studies – Participant Costs

– Identify all encounters and tasks

– Estimate costs of clinical procedures

– Estimate cost of clinical team member time for tasks without billing codes

Page 13: A Primer on Clinical Trials for the  Research Administrator David Lynch –

All Studies – Participant CostsText provides an example of a template to budget these costs.

Page 14: A Primer on Clinical Trials for the  Research Administrator David Lynch –

All Studies – Non-Participant CostsText provides an example of a template to budget these costs.

Page 15: A Primer on Clinical Trials for the  Research Administrator David Lynch –

All Studies – Non-Participant Costs

– Ideal situation is for sponsor reimbursement to include (a) a per participant reimbursement reflective of only variable costs and (b) separately invoice-able provision for fixed costs.

– If sponsor includes both fixed and variable costs in the per participant reimbursement, the recovery of fixed costs is then dependent on enrollment.• Text provides an example to demonstrate the financial

risks associated with this scenario.

Page 16: A Primer on Clinical Trials for the  Research Administrator David Lynch –

Indirect Cost Rate

– Federal sponsor – use negotiated rate; remember there are costs excluded from the application of the rate

– Non-federal sponsors – best practice is to have a documented policy (i.e. standard rate)

Page 17: A Primer on Clinical Trials for the  Research Administrator David Lynch –

Inflation Considerations

– Apply an inflation factor if the clinical study is anticipated to be active more than twelve months, considering • timing of expected enrollment; and• whether costs are concentrated to particular periods of

the study

- Text provides examples of considerations

Page 18: A Primer on Clinical Trials for the  Research Administrator David Lynch –

Negotiation Tips

– Consistent approach to budgeting and documentation

– Consideration of deficits and surpluses

– Timing of Payments

Page 19: A Primer on Clinical Trials for the  Research Administrator David Lynch –

Contents of Chapter Three“Contracting with Industry”

• Liability Issues• Confidentiality, Publication and Use of Data/Data

Ownership• General Contract Terms• Intellectual Property• Appendix with Templates

Page 20: A Primer on Clinical Trials for the  Research Administrator David Lynch –

Liability Issues

Indemnification• One party’s obligation to take responsibility for the legal

liability of another party

Insurance• Adequate amounts of insurance will be maintained by the

sponsor throughout the study period and for some time afterwards.

Page 21: A Primer on Clinical Trials for the  Research Administrator David Lynch –

Liability Issues

InsuranceText contains “Risk Assessment and

Insurance Score Card”.

Page 22: A Primer on Clinical Trials for the  Research Administrator David Lynch –

Liability Issues

Subject Injury

• Define who will be responsible for providing care to treat injuries and who will pay such costs

Page 23: A Primer on Clinical Trials for the  Research Administrator David Lynch –

Confidentiality

• Generally requires the most negotiation

• Openness in research and academic freedom versus secrecy and control of information

• Define the term “Confidential Information” and the timeframe involved

Page 24: A Primer on Clinical Trials for the  Research Administrator David Lynch –

Publication

• PI must have freedom to publish (written and unwritten).

• Sponsor should never be given editorial rights, only the ability to review and comment.

• Case study provided in text.

Page 25: A Primer on Clinical Trials for the  Research Administrator David Lynch –

Use of Data / Data Ownership

• Overarching principle is that the Principal Investigator may freely use the data generated by the study for future research and educational purposes.

Page 26: A Primer on Clinical Trials for the  Research Administrator David Lynch –

General Contract Terms

• The text provides and explains the terms and conditions often included in clinical trial agreements.

(Recitals, Period of Performance, Use of Name, Severability, Waiver, Notices, et cetera)

Page 27: A Primer on Clinical Trials for the  Research Administrator David Lynch –

Intellectual Property (IP)

• Maintain the institution’s right to use the IP that may be transferred to the sponsor (consistent with the institution’s research mission and non-profit status)

Page 28: A Primer on Clinical Trials for the  Research Administrator David Lynch –

Contents of Chapter Four“Financial Oversight of a Clinical Trial”

• Maintaining Participant-Level Information• Effort of Clinical Trial Team Members• Sponsor Reimbursement• Close Out• Appendix with Templates

Page 29: A Primer on Clinical Trials for the  Research Administrator David Lynch –

Maintaining Participant-Level Information

• Create a grid whereby each column corresponds to tasks conducted chronologically throughout the study for which the sponsor is to pay the cost

• Each row is assigned to a participant enrolled in the study with respective dates the participant completes each procedure/visit.

• Reconcile to the clinical study’s general ledger

Page 30: A Primer on Clinical Trials for the  Research Administrator David Lynch –

Maintaining Participant-Level InformationText provides an example of a grid

Page 31: A Primer on Clinical Trials for the  Research Administrator David Lynch –

Effort of Clinical Trial Team Members

• Allocate a reasonable percentage of each clinical trial team member’s effort directly to each clinical trial account

• During each trial’s life, staff can account for time spent on trial activities to assist with reasonableness of allocations.

• Reconcile to the clinical study’s general ledger

Page 32: A Primer on Clinical Trials for the  Research Administrator David Lynch –

Sponsor Reimbursement

• When payment is based on case report forms, ensure completeness of payments received.

• When payment is based on milestones and associated invoice preparation– Maintain a list of invoices sent and payments received– Follow-through on unpaid amounts– Adopt standard payment terms

Page 33: A Primer on Clinical Trials for the  Research Administrator David Lynch –

Close Out

• Require a thorough review of final clinical study account balances

• Identify reasons for deficits or residuals

• Text provides an example of a policy regarding usage of clinical study residuals.

Page 34: A Primer on Clinical Trials for the  Research Administrator David Lynch –

Contents of Chapter Five“Other Institutional Considerations”

• Conflict of Interest• Billing Compliance• Unrelated Business Income• Centralized and External IRB Review• Clinical Research Administration Organization• Standard Operating Procedures• Appendix with List of Regulations Related to Clinical Research

Page 35: A Primer on Clinical Trials for the  Research Administrator David Lynch –

Conflict of Interest

• Public Health Service issued regulations to provide standards to manage, reduce or eliminate financial conflicts of interest.

• Applies to IRB members, investigators, study coordinators, the institution, and others

• Real or potential conflicts

Page 36: A Primer on Clinical Trials for the  Research Administrator David Lynch –

Billing Compliance

• Adoption of Clinical Research Billing Policy• Education and training of employees• Mandatory billing plan/billing grid • Implement scheduling and registration controls• Implement clinical trial management system that verifies

correct billing • Perform routine internal auditing

Page 37: A Primer on Clinical Trials for the  Research Administrator David Lynch –

Unrelated Business Income

• Academic medical centers may be required to pay taxes on business income that is unrelated to the entity’s tax-exempt purpose.

• Avoid tax by establishing institutional policies interpreting its educational and research missions and strategic research operations

Page 38: A Primer on Clinical Trials for the  Research Administrator David Lynch –

Unrelated Business Income

• Conducting research is an exempt activity if “scientific research” is carried out in the “public interest”.

• Best practice is a formal policy which requires, or encourages, publication of research results in a timely manner.

Page 39: A Primer on Clinical Trials for the  Research Administrator David Lynch –

Organization Structure

• No “right way” – it depends on the culture or tradition of the institution

• Centralization– Advantages and disadvantages

• Decentralization– Advantages and disadvantages

Page 40: A Primer on Clinical Trials for the  Research Administrator David Lynch –

Thank you!